Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2086 to 2100 of 9026 results

  1. Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Botulinum neurotoxin type E for treating moderate to severe glabellar lines [TSID12155]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Nifedipine - Lidocaine for Chronic Anal Fissure [TSID 12093]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. iQoro neuromuscular training device, (MT809)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. MT656 Paige Prostate AI system for the detection of prostate cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. Bepirovirsen for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Camizestrant as an add-on to a first-line CDK4/6 inhibitor for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation [ID6535]

    Awaiting development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date: TBC

    NICE guideline
    In development